Abiopharma

🔍 Ciongoli Gregory Austin (Executive)

Company: REGENXBIO Inc. (RGNX)

Report Date: 2026-08-25

Detailed Transactions and Holdings:

• Acquired 15,432 shares of Common Stock (Direct)
  Date: 2026-08-25 | Code: A | equity_swap_involved: false | shares_owned_after: 15,432.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 49,196 shares of Common Stock at $9.1411 per share (Direct)
  Date: 2026-08-26 | Code: P | equity_swap_involved: false | shares_owned_after: 64,628.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 53,407 shares of Common Stock at $9.356 per share (Direct)
  Date: 2026-08-27 | Code: P | equity_swap_involved: false | shares_owned_after: 118,035.00 | transaction_form_type: 4 | Footnotes: F3
• Acquired 69,609 shares of Stock Options (Right to buy) at $8.91 per share (Derivative)
  Date: 2026-08-25 | Code: A | Expires: 2036-08-25 | Exercise: 2027-08-25 | equity_swap_involved: false | shares_owned_after: 69,609.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 1/3rd of the shares subject to the RSU award shall vest on each of August 25, 2027, August 25, 2028 and August 25, 2029, while the recipient provides continuous service to the Issuer.
• F2: Represents shares purchased in an open-market transaction. The price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $8.67 to $9.35. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F3: Represents shares purchased in an open-market transaction. The price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $9.17 to $9.4525. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F4: The option will vest over a three year period, with 1/3rd of the option vesting on August 25, 2027 and the remaining portion of the option vesting in equal monthly installments over the 24 months thereafter, while the optionee provides continuous service to the Issuer.